Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days

Executive Summary

Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications

You may also be interested in...



Ivax Glucophage XR Generic Exclusivity Extended; New Twist On “Late-List”

Ivax will gain at least an additional 30 days of generic marketing exclusivity for Bristol-Myers Squibb's Glucophage XR after a federal judge issued a temporary restraining order blocking FDA from approving other metformin extended-release ANDAs

Ivax Glucophage XR Generic Exclusivity Extended; New Twist On “Late-List”

Ivax will gain at least an additional 30 days of generic marketing exclusivity for Bristol-Myers Squibb's Glucophage XR after a federal judge issued a temporary restraining order blocking FDA from approving other metformin extended-release ANDAs

Andrx Fortamet Approved: Dosing Convenience Will Be Marketing Focus

Andrx will highlight the dosing convenience for Fortamet (metformin extended-release) in an effort to distinguish the antidiabetic agent from Glucophage XR and its generics

Related Content

UsernamePublicRestriction

Register

PS042914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel